Ron Wald
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ron Wald has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Bertrand L. Jaber
Division of Nephrology St. Elizabeth's Medical Center Boston Massachusetts
2 shared publicationsAlexey Kolyada
Division of Nephrology St. Elizabeth's Medical Center Boston Massachusetts
1 shared publicationC. David Mazer
Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael's Hospital Toronto Ontario Canada
1 shared publicationDamon C. Scales
1 shared publicationHeather Fieghen
Division of Nephrology, St. Michael's Hospital, University of Toronto, Toronto, Ont., Canada
1 shared publicationJin Luo
1 shared publication
Latest Publications
- Open Access
- 1 August 2010
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 5 (8) , 1373-1379
Plasma Cystatin C and Acute Kidney Injury after Cardiopulmonary Bypass
Background and objectives: Little is known about the performance of plasma cystatin C (CysC) in patients undergoing cardiopulmonary bypass (CPB) and its utility in the early diagnosis of acute kidney injury (AKI). In this post hoc analysis, the goal was to determine whether plasma cystatin C, measured 2 hours after the conclusion of CPB, is a reliable marker of AKI. Design, setting, participants, & measurements: Plasma CysC was measured in 150 patients undergoing CPB at the following times: preoperatively, 2 hours after the conclusion of CPB, postoperative day 1, and postoperative day 2. Plasma CysC levels were related to the development of AKI as defined by an increase in serum creatinine of ≥50% or ≥0.3 mg/dl from baseline up to 3 days postoperative. Mixed linear models were used to evaluate the relationship of serial plasma CysC values with AKI. The discriminatory capacity of plasma CysC was estimated using receiver operating characteristic curves. Logistic regression was utilized to assess the adjusted relationship between plasma CysC and subsequent AKI. Results: AKI developed in 47 (31.3%) patients. Plasma CysC was higher at all times among patients who developed AKI compared with those who did not (P < 0.0001). The discriminatory capacity of plasma CysC measured preoperatively and 2 hours after the conclusion of CPB was modest. Conclusions: Serial measures of plasma CysC are highly correlated with the development of AKI. However, the discriminatory capacity of plasma CysC as an early marker of AKI remains limited.
- 1 August 2010
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 5 (8) , 1373-1379
Open AccessPlasma Cystatin C and Acute Kidney Injury after Cardiopulmonary Bypass
Background and objectives: Little is known about the performance of plasma cystatin C (CysC) in patients undergoing cardiopulmonary bypass (CPB) and its utility in the early diagnosis of acute kidney injury (AKI). In this post hoc analysis, the goal was to determine whether plasma cystatin C, measured 2 hours after the conclusion of CPB, is a reliable marker of AKI. Design, setting, participants, & measurements: Plasma CysC was measured in 150 patients undergoing CPB at the following times: preoperatively, 2 hours after the conclusion of CPB, postoperative day 1, and postoperative day 2. Plasma CysC levels were related to the development of AKI as defined by an increase in serum creatinine of ≥50% or ≥0.3 mg/dl from baseline up to 3 days postoperative. Mixed linear models were used to evaluate the relationship of serial plasma CysC values with AKI. The discriminatory capacity of plasma CysC was estimated using receiver operating characteristic curves. Logistic regression was utilized to assess the adjusted relationship between plasma CysC and subsequent AKI. Results: AKI developed in 47 (31.3%) patients. Plasma CysC was higher at all times among patients who developed AKI compared with those who did not (P < 0.0001). The discriminatory capacity of plasma CysC measured preoperatively and 2 hours after the conclusion of CPB was modest. Conclusions: Serial measures of plasma CysC are highly correlated with the development of AKI. However, the discriminatory capacity of plasma CysC as an early marker of AKI remains limited.
- Top Cited PapersOpen Access
- 16 September 2009
- Published by American Medical Association (AMA) in JAMA
- Vol. 302 (11) , 1179-1185
Chronic Dialysis and Death Among Survivors of Acute Kidney Injury Requiring Dialysis
Acute kidney injury, which leads to a sudden decline in kidney function, is a common and serious complication of hospitalization in the adult population.1-4 Many patients with severe acute kidney injury require initiation of hemodialysis or hemofiltration (termed dialysis throughout), and their in-hospital mortality rate ranges from 45% to 70%.5-12 Among those who survive, as many as 15% require dialysis at the time of discharge.6,9
- 16 September 2009
- Published by American Medical Association (AMA) in JAMA
- Vol. 302 (11) , 1179-1185
Top Cited PapersOpen AccessChronic Dialysis and Death Among Survivors of Acute Kidney Injury Requiring Dialysis
Acute kidney injury, which leads to a sudden decline in kidney function, is a common and serious complication of hospitalization in the adult population.1-4 Many patients with severe acute kidney injury require initiation of hemodialysis or hemofiltration (termed dialysis throughout), and their in-hospital mortality rate ranges from 45% to 70%.5-12 Among those who survive, as many as 15% require dialysis at the time of discharge.6,9
- Open Access
- 16 June 2009
- Published by S. Karger AG in Nephron Clinical Practice
- Vol. 112 (4) , c222-c229
Renal Replacement Therapy for Acute Kidney Injury
The treatment of established acute kidney injury (AKI) is largely supportive in nature. Renal replacement therapy remains the cornerstone of management for the minority of patients who have severe AKI. Optimization of renal replacement therapy may modulate the high mortality associated with AKI. Recent trials indicated that continuous renal replacement therapy does not confer a survival advantage as compared to intermittent hemodialysis. Furthermore, there is no evidence to support a more intensive strategy of renal replacement therapy in the setting of AKI. There is comparatively limited data regarding the ideal timing of renal replacement therapy initiation and the preferred mode of solute clearance.
- 16 June 2009
- Published by S. Karger AG in Nephron Clinical Practice
- Vol. 112 (4) , c222-c229
Open AccessRenal Replacement Therapy for Acute Kidney Injury
The treatment of established acute kidney injury (AKI) is largely supportive in nature. Renal replacement therapy remains the cornerstone of management for the minority of patients who have severe AKI. Optimization of renal replacement therapy may modulate the high mortality associated with AKI. Recent trials indicated that continuous renal replacement therapy does not confer a survival advantage as compared to intermittent hemodialysis. Furthermore, there is no evidence to support a more intensive strategy of renal replacement therapy in the setting of AKI. There is comparatively limited data regarding the ideal timing of renal replacement therapy initiation and the preferred mode of solute clearance.